Puma Biotechnology (PBYI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$231.2M

Revenue (quarter)

$56.5M

Revenue growth (year over year)

+7.75%

Gross profit (trailing twelve months)

$173.0M

Gross margin

74.83%

Net income (trailing twelve months)

$26.7M

Net income (quarter)

$8.2M

Net income growth (year over year)

+39.86%

Net margin

11.55%

Return on equity

21.97%

EPS (trailing twelve months)

$0.53

Book value per share

$2.71

P/E (trailing twelve months)

19.55

Price to book

3.77

Debt to assets

28.12%

Payout ratio

—

Dividend yield

—

Company profile

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

• Is Puma Biotechnology (PBYI) profitable?

  Yes. Puma Biotechnology earned $26.7M in net income over the trailing twelve months, a net margin of 11.55%.

• How much revenue does Puma Biotechnology (PBYI) make?

  Puma Biotechnology generated $231.2M in revenue over the trailing twelve months, up 7.75% year over year.

• What is PBYI's P/E ratio?

  Puma Biotechnology trades at 19.6 times trailing twelve-month earnings, on an EPS of $0.53.

• How do I buy stock in Puma Biotechnology (PBYI)?

  PBYI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.